- Home
- HRMY vs STEW Comparison
HRMY vs STEW Comparison
Compare HRMY & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- STEW
- Stock Information
- Founded
- HRMY 2017
- STEW 1972
- Country
- HRMY United States
- STEW United States
- Employees
- HRMY N/A
- STEW N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- STEW Investment Managers
- Sector
- HRMY Health Care
- STEW Finance
- Exchange
- HRMY Nasdaq
- STEW Nasdaq
- Market Cap
- HRMY 2.1B
- STEW 1.7B
- IPO Year
- HRMY 2020
- STEW N/A
- Fundamental
- Price
- HRMY $35.99
- STEW $18.47
- Analyst Decision
- HRMY Strong Buy
- STEW
- Analyst Count
- HRMY 9
- STEW 0
- Target Price
- HRMY $55.33
- STEW N/A
- AVG Volume (30 Days)
- HRMY 531.4K
- STEW 84.5K
- Earning Date
- HRMY 10-28-2025
- STEW 01-01-0001
- Dividend Yield
- HRMY N/A
- STEW 3.71%
- EPS Growth
- HRMY 58.41
- STEW N/A
- EPS
- HRMY 3.10
- STEW 1.44
- Revenue
- HRMY $772,527,000.00
- STEW N/A
- Revenue This Year
- HRMY $20.09
- STEW N/A
- Revenue Next Year
- HRMY $16.74
- STEW N/A
- P/E Ratio
- HRMY $11.61
- STEW $10.34
- Revenue Growth
- HRMY 17.74
- STEW N/A
- 52 Week Low
- HRMY $26.47
- STEW $11.97
- 52 Week High
- HRMY $41.61
- STEW $14.94
- Technical
- Relative Strength Index (RSI)
- HRMY 47.09
- STEW 67.65
- Support Level
- HRMY $36.50
- STEW $17.93
- Resistance Level
- HRMY $38.28
- STEW $18.58
- Average True Range (ATR)
- HRMY 0.95
- STEW 0.14
- MACD
- HRMY -0.17
- STEW 0.03
- Stochastic Oscillator
- HRMY 9.84
- STEW 74.04
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.